 |
SuperGen's CLIMB(TM) Technology Identifies Lead Pim Kinase Inhibitors
Dec 10, 2007
|
5.5 KB |
|
| |
ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a
pharmaceutical company dedicated to the discovery, rapid development and commercialization
of therapies for solid tumors and hematological malignancies, today announced
the presentation of data that describe how its proprietary CLIMB™...
|
|
SuperGen's Novel Hypomethylating Agent Highlighted at American Society of Hematology Annual Meeting
Dec 10, 2007
|
6.8 KB |
|
| |
ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a
pharmaceutical company dedicated to the discovery, rapid development and
commercialization of therapies for solid tumors and hematological
malignancies, today announced the presentation of data that describe how its
novel decitabine dinucleotide compound, S110, activa...
|
|
SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the American Society of Hematology's 49th Annual Meeting
Dec 3, 2007
|
6.0 KB |
|
| |
DUBLIN, Calif., Dec. 3 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced that multiple abstracts have been
accepted for presentation at the American Society of Hemato...
|
|
Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting
Nov 29, 2007
|
49.6 KB |
|
| |
Astex Therapeutics Ltd. today announced that data on its drug candidates AT9283, AT7519 and AT9311 will be presented at the American Society of Hematology’s 49th Annual Meeting and Exposition, 8-11th December 2007, at the Georgia World Congress Center, Atlanta, Georgia.
AT9283 is an inhibitor of the kinases Aurora A, Aurora B, JAK2...
|
|
Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme
Oct 31, 2007
|
7.2 KB |
|
| |
DUBLIN, Calif., Oct. 31 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced during an oral presentation at the
American Society for Therapeutic Radiology and Oncology's...
|
|
SuperGen Reports 2007 Third Quarter Financial Results
Oct 29, 2007
|
14.9 KB |
|
| |
DUBLIN, Calif., Oct. 29 /PRNewswire-FirstCall/ -- SuperGen Inc.,
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today reported financial results for the third
quarter and nine months ended September 30, 2007.
...
|
|
SuperGen's Novel Hypomethylating Agent Highlighted at AACR Plenary Session
Oct 25, 2007
|
6.4 KB |
|
| |
SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced as part of a series of
presentations at the 2007 AACR-NCI-EORTC International Conference that...
|
|
Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Synergy with DNA Damaging Agents
Oct 25, 2007
|
6.4 KB |
|
| |
SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced as part of a series of
presentations at the 2007 AACR-NCI-EORTC International Conference that...
|
|
Data Support use of SuperGen's CLIMB Technology in Lead Development and Optimization
Oct 25, 2007
|
6.4 KB |
|
| |
SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced data as part of a series of
presentations at the 2007 AACR-NCI-EORTC International Conference...
|
|
Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 18, 2007
|
12.5 KB |
|
| |
Astex Therapeutics Ltd. today announced that data on two of its drug candidates, AT7519 and AT13148, will be presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, to be held October 22-26, 2007 in San Francisco.
AT7519 is a potent and selective Cyclin Dependent Kinase (CDK) inhibitor ...
|
|
SuperGen to Webcast Investigator/Analyst Pipeline Update Presentation October 24
Oct 18, 2007
|
5.2 KB |
|
| |
DUBLIN, Calif., Oct. 18 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced that it will webcast its
investigator/analyst pipeline update presentation beginning at 7:50...
|
|
SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
Oct 17, 2007
|
6.7 KB |
|
| |
DUBLIN, Calif., Oct. 17 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced that multiple abstracts have been
accepted for poster presentations at the AACR-NCI-EORTC In...
|
|
Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer
Aug 17, 2007
|
4.8 KB |
|
| |
DUBLIN, Calif., Aug 17, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced that Audrey F. Jakubowski, Ph.D.,
Chief Regulatory and Quality ...
|
|
SuperGen Reports 2007 Second Quarter Financial Results
Aug 2, 2007
|
18.2 KB |
|
| |
Achieves net income of $11.1 million due to gain on sale of products
Doses first patient in Phase I trial of novel tyrosine kinase inhibitor
Announces first meeting of newly formed Scientific Advisory Board (SAB)
Hires Dr. Gregory Berk as Chief Medical Officer
...
|
|
SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine Kinase Inhibitor
Jul 5, 2007
|
7.5 KB |
|
| |
DUBLIN, Calif., July 5 /PRNewswire-FirstCall/ -- SuperGen, Inc.
(Nasdaq: SUPG) today announced that collaborators at The Translational
Genomics Research Institute (TGen) and TGen Clinical Research Services (TCRS)
at Scottsdale Healthcare in Scottsdale, Arizona, have dosed the first
patient in a Phase I clinical trial of MP470, a novel, oral,...
|
|
SuperGen Announces First Meeting of Newly Formed Scientific Advisory Board
May 30, 2007
|
7.8 KB |
|
| |
DUBLIN, Calif., May 30 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG) today announced that it has convened the first meeting of its
newly formed Scientific Advisory Board (SAB).
The SAB is composed of three external and two Company scientists with
expertise in the field of oncology whose role will be to help guide and
cou...
|
|
SuperGen Names Gregory Berk, M.D., Chief Medical Officer
May 29, 2007
|
6.4 KB |
|
| |
DUBLIN, Calif., May 29 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG) today announced the addition of Gregory Berk, M.D., to the
management team as Chief Medical Officer.
Dr. Berk, 49, will lead SuperGen's international clinical development
strategy, operations and safety divisions to rapidly advance the company's
oncolog...
|
|
SuperGen to Participate in Brean Murray Carret & Co. Healthcare & Biotechnology Small Cap One-on-One Conference
May 11, 2007
|
4.1 KB |
|
| |
DUBLIN, Calif., May 11 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG) today announced that it will participate in the Brean Murray
Carret & Co. Healthcare & Biotechnology Small Cap One-on-One Conference on
Tuesday, May 15, at the Grand Hyatt New York.
Dr. Michael McCullar, Vice President, Drug Discovery Operations,...
|
|
SuperGen Reports 2007 First Quarter Financial Results
May 2, 2007
|
14.9 KB |
|
| |
DUBLIN, Calif., May 2 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG) today reported financial results for the first quarter ended
March 31, 2007.
Total revenues for the 2007 first quarter were $4.4 million compared with
$2.9 million for the same prior year period. Total revenues for the 2007
first quarter includes $3.8 m...
|
|
SuperGen Receives FDA Clearance to Initiate Phase I Clinical Trial With MP470
Apr 27, 2007
|
6.4 KB |
|
| |
DUBLIN, Calif., April 25 /PRNewswire/ -- SuperGen Inc. (Nasdaq: SUPG - News) today announced that the Food and Drug Administration cleared MP470, a novel oral multi-targeted tyrosine kinase inhibitor (TKI), for a first-in-human Phase I clinical trial.
The Phase I accelerated titration dose-escalation trial will assess the safety and to...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter